Table 2. Change from baseline in gene expression after 1 month of treatment with recombinant human growth hormone.
| Parameter | GHD | TS |
|---|---|---|
| Number of probes detected | 24 707 | 25 313 |
| Upregulated genes, n (%) | 13 242 (53.6) | 13 906 (54.9) |
| Downregulated genes, n (%) | 11 465 (46.4) | 11 407 (45.1) |
| Maximum-fold change | ||
| Upregulated genes | 1.58 | 1.37 |
| Downregulated genes | −1.37 | −1.33 |
| Gene probe sets with a significant expression change from baseline | 5367 | 1850 |
| Unadjusted P-value<0.05 | ||
| Upregulated, n (%) | 3556 (66.3) | 1178 (63.7) |
| Downregulated, n (%) | 1811 (33.7) | 672 (36.3) |
| FDR<0.1 | 1505 | 3 |
| Upregulated, n (%) | 1122 (74.6) | 1 (33.3) |
| Downregulated, n (%) | 383 (25.4) | 2 (66.7) |
Abbreviations: FDR, false discovery rate; GHD, growth hormone deficiency; TS, Turner syndrome.
Gene expression was assessed using the Affymetrix Human Genome U133 Plus 2.0 microarray system. Age-related gene expression probes were removed and the final number of probes detected was further adjusted for probes with low variance (σ/σmax=0.05). The overlap of gene expression probe sets between GHD and TS was 552 (P<0.05), representing 446 genes.